CN108409938A - A kind of novel degradable polyurethane biomaterial and its preparation method and application - Google Patents
A kind of novel degradable polyurethane biomaterial and its preparation method and application Download PDFInfo
- Publication number
- CN108409938A CN108409938A CN201810111018.7A CN201810111018A CN108409938A CN 108409938 A CN108409938 A CN 108409938A CN 201810111018 A CN201810111018 A CN 201810111018A CN 108409938 A CN108409938 A CN 108409938A
- Authority
- CN
- China
- Prior art keywords
- block
- polyurethane
- holder
- wound
- diisocyanate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004814 polyurethane Substances 0.000 title claims abstract description 83
- 229920002635 polyurethane Polymers 0.000 title claims abstract description 83
- 239000012620 biological material Substances 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000000463 material Substances 0.000 claims abstract description 56
- 210000000744 eyelid Anatomy 0.000 claims abstract description 35
- 230000008439 repair process Effects 0.000 claims abstract description 35
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 34
- 238000002513 implantation Methods 0.000 claims abstract description 28
- 210000005036 nerve Anatomy 0.000 claims abstract description 23
- 229920000642 polymer Polymers 0.000 claims abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229920003232 aliphatic polyester Polymers 0.000 claims abstract description 15
- 125000005442 diisocyanate group Chemical group 0.000 claims abstract description 15
- 229920000570 polyether Polymers 0.000 claims abstract description 9
- 210000004872 soft tissue Anatomy 0.000 claims abstract description 9
- 239000004721 Polyphenylene oxide Substances 0.000 claims abstract description 8
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 8
- 210000003625 skull Anatomy 0.000 claims description 27
- 230000037314 wound repair Effects 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 15
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 14
- 210000000578 peripheral nerve Anatomy 0.000 claims description 10
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- 230000003796 beauty Effects 0.000 claims description 7
- -1 lysine ester Chemical class 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 229920000728 polyester Polymers 0.000 claims description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 4
- 210000000845 cartilage Anatomy 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- 230000023597 hemostasis Effects 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 4
- 229920000742 Cotton Polymers 0.000 claims description 3
- 206010019909 Hernia Diseases 0.000 claims description 3
- 239000005057 Hexamethylene diisocyanate Substances 0.000 claims description 3
- 239000005058 Isophorone diisocyanate Substances 0.000 claims description 3
- 208000031888 Mycoses Diseases 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 230000002439 hemostatic effect Effects 0.000 claims description 3
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 claims description 3
- 239000012948 isocyanate Substances 0.000 claims description 3
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 claims description 3
- 150000002513 isocyanates Chemical class 0.000 claims description 3
- NIMLQBUJDJZYEJ-UHFFFAOYSA-N isophorone diisocyanate Chemical compound CC1(C)CC(N=C=O)CC(C)(CN=C=O)C1 NIMLQBUJDJZYEJ-UHFFFAOYSA-N 0.000 claims description 3
- AYLRODJJLADBOB-QMMMGPOBSA-N methyl (2s)-2,6-diisocyanatohexanoate Chemical compound COC(=O)[C@@H](N=C=O)CCCCN=C=O AYLRODJJLADBOB-QMMMGPOBSA-N 0.000 claims description 3
- 230000017423 tissue regeneration Effects 0.000 claims description 3
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical class OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 claims description 2
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 claims description 2
- 238000006116 polymerization reaction Methods 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- KORSJDCBLAPZEQ-UHFFFAOYSA-N dicyclohexylmethane-4,4'-diisocyanate Chemical compound C1CC(N=C=O)CCC1CC1CCC(N=C=O)CC1 KORSJDCBLAPZEQ-UHFFFAOYSA-N 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 abstract description 18
- 239000000126 substance Substances 0.000 abstract description 11
- 230000008929 regeneration Effects 0.000 abstract description 10
- 238000011069 regeneration method Methods 0.000 abstract description 10
- 238000005859 coupling reaction Methods 0.000 abstract description 7
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 238000011084 recovery Methods 0.000 abstract description 5
- 150000002009 diols Chemical class 0.000 abstract description 2
- 239000012528 membrane Substances 0.000 abstract description 2
- 238000000059 patterning Methods 0.000 abstract description 2
- 229920000229 biodegradable polyester Polymers 0.000 abstract 1
- 239000004622 biodegradable polyester Substances 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 description 65
- 206010052428 Wound Diseases 0.000 description 62
- 241000700159 Rattus Species 0.000 description 31
- 230000002980 postoperative effect Effects 0.000 description 24
- 230000000694 effects Effects 0.000 description 23
- 230000007547 defect Effects 0.000 description 15
- 230000006378 damage Effects 0.000 description 13
- 239000006260 foam Substances 0.000 description 13
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 13
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 13
- 238000006731 degradation reaction Methods 0.000 description 12
- 230000015556 catabolic process Effects 0.000 description 11
- 239000004632 polycaprolactone Substances 0.000 description 11
- 229920001610 polycaprolactone Polymers 0.000 description 11
- 210000000457 tarsus Anatomy 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 230000008602 contraction Effects 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 210000001508 eye Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- 230000001537 neural effect Effects 0.000 description 7
- 230000004224 protection Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000001506 calcium phosphate Substances 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 6
- 239000004626 polylactic acid Substances 0.000 description 6
- 229940078499 tricalcium phosphate Drugs 0.000 description 6
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 6
- 235000019731 tricalcium phosphate Nutrition 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 229920000954 Polyglycolide Polymers 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 210000004209 hair Anatomy 0.000 description 5
- 229920000747 poly(lactic acid) Polymers 0.000 description 5
- 239000004633 polyglycolic acid Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical class O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000150100 Margo Species 0.000 description 4
- 206010072170 Skin wound Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000005252 bulbus oculi Anatomy 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000000963 osteoblast Anatomy 0.000 description 4
- 229920001432 poly(L-lactide) Polymers 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000003497 sciatic nerve Anatomy 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 206010019196 Head injury Diseases 0.000 description 3
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010039509 Scab Diseases 0.000 description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000007831 electrophysiology Effects 0.000 description 3
- 238000002001 electrophysiology Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000007489 histopathology method Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 229920001451 polypropylene glycol Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 2
- 241000256856 Vespidae Species 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000000181 anti-adherent effect Effects 0.000 description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 230000003562 morphometric effect Effects 0.000 description 2
- 238000013425 morphometry Methods 0.000 description 2
- 230000007659 motor function Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 230000000278 osteoconductive effect Effects 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000010827 pathological analysis Methods 0.000 description 2
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 2
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920000909 polytetrahydrofuran Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000012974 tin catalyst Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 206010014568 Empyema Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- UKLDJPRMSDWDSL-UHFFFAOYSA-L [dibutyl(dodecanoyloxy)stannyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[Sn](CCCC)(CCCC)OC(=O)CCCCCCCCCCC UKLDJPRMSDWDSL-UHFFFAOYSA-L 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000003462 bioceramic Substances 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CWZPGMMKDANPKU-UHFFFAOYSA-L butyl-di(dodecanoyloxy)tin Chemical compound CCCC[Sn+2].CCCCCCCCCCCC([O-])=O.CCCCCCCCCCCC([O-])=O CWZPGMMKDANPKU-UHFFFAOYSA-L 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 238000005253 cladding Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000012975 dibutyltin dilaurate Substances 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000004728 ear cartilage Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000001983 hard palate Anatomy 0.000 description 1
- 201000000615 hard palate cancer Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 210000002239 ischium bone Anatomy 0.000 description 1
- 150000002527 isonitriles Chemical class 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229920001306 poly(lactide-co-caprolactone) Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/48—Polyethers
- C08G18/4825—Polyethers containing two hydroxy groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/06—At least partially resorbable materials
- A61L17/10—At least partially resorbable materials containing macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/64—Use of materials characterised by their function or physical properties specially adapted to be resorbable inside the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/60—Materials for use in artificial skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/30—Low-molecular-weight compounds
- C08G18/32—Polyhydroxy compounds; Polyamines; Hydroxyamines
- C08G18/3203—Polyhydroxy compounds
- C08G18/3206—Polyhydroxy compounds aliphatic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/4009—Two or more macromolecular compounds not provided for in one single group of groups C08G18/42 - C08G18/64
- C08G18/4018—Mixtures of compounds of group C08G18/42 with compounds of group C08G18/48
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/42—Polycondensates having carboxylic or carbonic ester groups in the main chain
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/42—Polycondensates having carboxylic or carbonic ester groups in the main chain
- C08G18/4266—Polycondensates having carboxylic or carbonic ester groups in the main chain prepared from hydroxycarboxylic acids and/or lactones
- C08G18/4269—Lactones
- C08G18/4277—Caprolactone and/or substituted caprolactone
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/42—Polycondensates having carboxylic or carbonic ester groups in the main chain
- C08G18/4266—Polycondensates having carboxylic or carbonic ester groups in the main chain prepared from hydroxycarboxylic acids and/or lactones
- C08G18/428—Lactides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/48—Polyethers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/48—Polyethers
- C08G18/4833—Polyethers containing oxyethylene units
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/48—Polyethers
- C08G18/4854—Polyethers containing oxyalkylene groups having four carbon atoms in the alkylene group
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
- C08G18/72—Polyisocyanates or polyisothiocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/32—Materials or treatment for tissue regeneration for nerve reconstruction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G2230/00—Compositions for preparing biodegradable polymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Materials For Medical Uses (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
A kind of novel degradable polyurethane biomaterial extremely preparation method and the application in preparing degradable implantation and non-implanted medical device.The new material is the alternating block polyurethane high molecule material obtained based on biodegradable polyester diol and Hydrophilicrto polyether dihydric alcohol, is obtained by the selectively coupled reaction between aliphatic polyester binary alcohol and diisocyanate terminated Hydrophilicrto polyether or between aliphatic poly esterdiol and diisocyanate terminated aliphatic polyester block.Product of the present invention has the polymer chain of controllable and predictable chemical constitution and rule, and there is the patterning structure of surface microfacies, many medical treatment and non-medical instrument field are can be widely applied to, wherein all showing excellent performance in the applications such as periphery nerve rehabilitating tube, meniscal repairs, anti-adhesion membrane, meninx, eyelid rebuilding holder, wound dressing, the compound porous recovery support of bone, other soft tissues and the regeneration of sclerous tissues.
Description
Technical field
The present invention relates to biomedical polymeric material field, especially a kind of novel degradable polyurethane biomaterial and
Preparation method and application.
Background technology
Biodegradable block polyurethane is a kind of widely used biomaterial, has had several moneys to plant accordingly at present
Enter medical instrument and obtains the approval of European CE and U.S. FDA applied to human body.Due to its excellent blood compatibility, excellent
Machinery and processing performance are widely used in the application necks such as organizational project, regenerative medicine, control drug delivery, wound healing
Domain.However, almost all of tradition block polyurethane is all using diisocyanate as coupling agent, by dihydric alcohol or/and more
The terminal hydroxyl of first alcohol is synthesized with the coupling reaction of isocyanates, though this method provides the materials with improved property, but
Actually it lacks the permutation and combination of block selectivity and rule, and can only become block copolymer by assembly and connection in a random basis
(i.e. traditional random block polyurethane macromolecule, abbreviation:RanPU, as shown in Figure 1), and this kind of random structure will lead to material
Property is difficult to.
Invention content
For overcome the deficiencies in the prior art, the present invention provides a kind of novel degradable polyurethane biomaterial and its systems
Preparation Method, the material have good blood compatibility, histocompatbility, have excellent surface nature, mechanical mechanics property,
Moulding processability and biodegradability, pH caused by catabolite are changed very little, and are conducive to the raising of biocompatibility.
The technical solution adopted by the present invention to solve the technical problems is:
Present invention firstly provides a kind of novel degradable polyurethane biomaterial, including several formed by first polymer
First block, several the second blocks formed by second polymer, the first block and the second block are alternately arranged, and adjacent first
Be keyed to form alternating block polyurethane (AltPU) by carbamate between block and the second block, as it is described it is novel can
Degradable polyurethane biomaterial;
Wherein, the first polymer is the polyester of dihydric alcohol sealing end, and the second polymer is diisocyanate terminated
Aliphatic polyether or aliphatic polyester polymers, the second polymer can also be substituted by aliphatic dihydroxy alcohol, such as second
Glycol, 1,4- butanediols etc..
Preferably, the polyester of the dihydric alcohol sealing end is that aliphatic polyester or different aliphatic polyesters combine the copolymerization to be formed
Object.
Preferably, the diisocyanate is aliphatic diisocyanate, specially hexamethylene diisocyanate, fourth two
Isocyanates, lysine diisocyanate, ethyl ester of lysine diisocyanate, isophorone diisocyanate, 4,4'- methylene
One kind in bis- (cyclohexyl) diisocyanate, the conjunction for the diisocyanate terminated segment in synthesis of selective coupling reaction
At.
The present invention also provides a kind of preparation methods of above-mentioned novel degradable polyurethane biomaterial, polymerize with described first
Object and second polymer are reaction raw materials, are reacted 8~72 hours at 30~100 DEG C, obtain the alternating block polyurethane.
Preferably, above-mentioned reaction carries out in reaction raw materials ontology or organic solvent, can also be added in reaction system
Machine tin catalyst.
Preferably, hydroxyl is identical with the molar ratio of isocyanate groups in the reaction raw materials.
Above-mentioned novel degradable polyurethane biomaterial can be used for preparing implantation and non-implanted medical device.
Above-mentioned novel degradable polyurethane biomaterial can be applied to but be not limited to prepare following degradable medical apparatus:
Soft tissue regeneration reparation, as Peripheral nerve repair socket pipe, Peripheral nerve repair coating film, Peripheral nerve repair are protected
Bluff piece;
Artificial skin regenerates;
Biodegradable coating, as the degradable drug-carried coat of intravascular stent, foot fungus infection treat drug-carried coat;
Adherence preventing material, such as operation antiblocking film, cranium brain film;
Cartilage complex repairation holder, such as meniscal repairs porous plate, eyelid reconstruction holder;
Wound repair film and dressing, such as liquid adhesive bandage, negative pressure drainage dressing, hemostatic yarn, ear nose hemostasis cotton;
Bone complex repairation holder, such as the compound porous recovery support of skull;
Special medical absorbable suture, such as elastic force operation suture thread;
It is other can et al. Ke medical instrument and medical and beauty treatment product, as hernia repair sticking patch, soft tissue lift belt (line).
The positive effect of the present invention:This is to invent this kind of to there is segment to be alternately arranged new structural can give birth to completely for the first time
Object degradation block polyurethane material.Novel degradable polyurethane biomaterial, that is, alternating block polyurethane of the present invention
(AltPU) it is developed as a new class of block polyurethane biomaterial comprising block is alternately arranged (as shown in Figure 1).
These block polyurethanes have the physics microstructure of controllable chemical constitution and rule.With good controllable chemical constitution
And the surface microstructure of rule, compared with RanPU, AltPU has higher crystallinity, higher surface energy more regular
With stable picture on surface.Its alternating structure increases microphase-separated, to allow some segments such as to be moved than more hydrophilic segment
It moves on material surface, to have higher surface energy;Higher crystallinity enhances mechanical strength, and alternating structure causes to have
Well-regulated surface.The roughness on surface is further studied by atomic force microscope (AFM), record has identical chemical composition
AltPU and RanPU height image, it is found that the Ra (mean roughness) of 101.8nm is presented in alternate AltPU material surfaces
With the Rmax (maximal roughness) of 762.9nm, it is significantly larger than the RanPU material tables that Ra is 47.6nm and Rmax is 387.9nm
The patterning structure in face, these surfaces is conducive to the adherency and growth of cell.Alternating block polyurethane (AltPU) of the present invention
Biomaterial is not only propped up in CO2 laser weld socket pipe, orthopaedics reparation, eyelid rebuilding holder, wound dressing and the compound porous reparation of bone
Good application effect is embodied on frame, in the application of other medical instruments, including skin reconstruction and reparation, Antiadhesive film, blood
Tubing patch film, meninx, ligament and tendon repair etc. also embody excellent repairing performance.
The block alternating structure of alternating block polyurethane of the present invention imparts this material many special properties and work(
Energy.Such as traditional PLLA, PLGA and/or based on the implantation instrument of PCL during degradation, significant change can occur for pH value
(increasing acidity), so as to cause the inflammation in local organization, influences the regeneration function of tissue, and can be to the performance of medical instrument
Have an adverse effect.And the implantation instrument made of the alternating block polyurethane (AltPU) of the present invention is only shown during degradation
Very small pH value variation, pH value variation are significantly smaller than raw material such as PCL and corresponding random block polyurethane material
Expect the pH value variation of Ran-PU.Since polyurethane has carbamate chemical structure, acid is generated simultaneously in degradation process
Property carboxyl and alkaline amido, this is different from aliphatic polyester such as PGA and PLA only generates acidic carboxypolymer during degradation, leads to fat
The pH of adoption ester implantation material regional area is significantly reduced, and is compared with PLLA, PLGA, and implantation material made of the material based on PCL,
The property of AltPU implantation materials of the present invention pH value minor change caused during degradation contributes to caused by reducing implantation material
Inflammatory reaction risk improves the reparative regeneration function of histoorgan.
Description of the drawings
Fig. 1:The high molecular schematic arrangement of traditional random block polyurethane;
Fig. 2:The schematic arrangement of alternating block polyurethane of the present invention;
Fig. 3 a:CO2 laser weld micrurgy schematic diagram;
Fig. 3 b:The CO2 laser weld socket pipe being implanted into rat body;
Fig. 3 c:By the SEM figures of socket pipe prepared by alternating block polyurethane (Alt-PU);
Fig. 4:Sciatic nerve function index (SFI) value during different materials group CO2 laser weld;
Fig. 5 a:The postoperative 4 weeks rats footprint figure of Alt-PU groups;
Fig. 5 b:The postoperative 8 weeks rats footprint figure of Alt-PU groups;
Fig. 5 c:The postoperative 14 weeks rats footprint figure of Alt-PU groups;
Fig. 6:Different phase electro physiology injury side peak swing and healthy side comparative situation;
Fig. 7 a:The postoperative 1h observation charts of Alt-PU group rats;
Fig. 7 b:The postoperative observation chart for 24 hours of Alt-PU group rats;
Fig. 7 c:The postoperative two weeks observation charts of Alt-PU group rats;
Fig. 7 d:The postoperative surrounding observation chart of Alt-PU group rats;
Fig. 8 a:Gauze group different periods skin ultrastructure compares figure;
Fig. 8 b:Ran-PU group different periods skin ultrastructure compares figures;
Fig. 8 c:Alt-PU group different periods skin ultrastructure compares figures;
Fig. 9:Contraction of wounds rate of each group in the different wound repair times;
Figure 10 a:The histopathological analysis figure of normal skin wound repair;
Figure 10 b:The histopathological analysis figure of Alt-PU group skin ultrastructures;
Figure 10 c:The histopathological analysis figure of gauze group skin ultrastructure;
Figure 11 a:Alt-PU porous foam bone repairing support SEM photographs without hydroxyapatite;
Figure 11 b:Alt-PU porous foam bone repairing support SEM photographs containing 90% weight percent hydroxyapatite;
Figure 11 c:Alt-PU porous foam bone repairing support SEM photographs containing 70% weight percent hydroxyapatite;
Figure 11 d:Alt-PU porous foam bone repairing support SEM photographs containing 50% weight percent hydroxyapatite;
Figure 11 e:Alt-PU porous foam bone repairing support SEM photographs containing 30% weight percent hydroxyapatite;
Figure 11 f:Polymetylmethacrylate rack surface SEM photograph without hydroxyapatite;
Figure 12 a:Half storey head injury figure is built on the right side of Rat calvarial;
Figure 12 b:Defect figure after experimental group stenter to implant 18 days;
Figure 12 c:Postoperative 40 days control group head injury area images;
Figure 12 d:Experimental group implantation holder head injury healing image after 80 days.
Specific implementation mode
Below to a preferred embodiment of the present invention will be described in detail, but embodiment the present invention is not done it is any type of
It limits.Reagent used in embodiment and device are all unless otherwise specified using this field common reagent and device.
Embodiment 1
Synthesize alternating block polyurethane (Alt-PU) and the poly- ammonia of random block based on aliphatic polyester and Hydrophilicrto polyether
Ester (Ran-PU):
In the organic solvent (chloroform) that aliphatic polyester binary alcohol is initially dissolved in three-neck flask, then it will utilize
Hydrophilicrto polyether-diisocyanate that end capping reaction is prepared is pressed and dihydric alcohol 1:1 molar equivalent is slowly dropped into flask
In, after reacting 8-72h at 30-100 DEG C, obtain alternating block polyurethane Alt-PU.Above-mentioned reaction also can be directly former in reaction
It is carried out in material ontology, one thousandth can also be used to the organotin catalysts of ten a ten thousandths (weight ratio), such as 2- ethyl hexyls
Sour tin, butyl tin dilaurate etc., hydroxyl and isocyanate groups should have equal molar ratio in reflection system.
It uses aliphatic polyester binary alcohol and Hydrophilicrto polyether as reacting body, tin-containing catalyst is added, while different with two
For cyanate as coupling agent, the amount of the diisocyanate of addition is equal to the amount of the substance of-OH groups in reaction solution, will react
Mixture stirs 8-72h at 30-100 DEG C under nitrogen protection, then collects product and is dried under vacuum to constant weight,
Obtain the random block polyurethane Ran-PU.
The following examples will be with CO2 laser weld socket pipe, eyelid rebuilding holder, wound dressing and the compound porous reparation of bone
Holder is representative, illustrate the alternating block polyurethane (AltPU) of preparation on applied to implanted medical device with it is other common
Degradable biomaterial compares possessed superiority.
Embodiment 2
By the alternating block polyurethane (Alt-PU) prepared in embodiment 1 and the biological material of random block polyurethane (Ran-PU)
Preparation of the material applied to CO2 laser weld socket pipe:
Porous CO2 laser weld socket pipe is prepared by using dip-coating and salt leaching method, uses the stainless steel wire that outer diameter is 1.5mm
As mold, then the polymer coating on the mold of gained is air-dried 2 days, vacuum drying 2 days, then in deionized water
Salt is leached, freeze-drying and demoulding obtain CO2 laser weld socket pipe.
CO2 laser weld socket pipe, also referred to as nerve rehabilitating tube or CO2 laser weld sheath;It may also be referred to as CO2 laser weld cladding
Piece and neuroprotection open tube.CO2 laser weld socket pipe prepared by the alternating block polyurethane (Alt-PU) has porosity
For 10-99% and microporous pipeline structure, micropore laminated structure and pore openings pipeline that aperture is 100nm to 500 μm (micron)
Structure.
The CO2 laser weld socket pipe can also include bioactive substance, such as reactive protein RGD, nerve growth
The factor (NGF), nerve growth drug, schwann cell and other neural benefit materials.
Peripheral nerve defect is very common clinical wound, and frequently result in patient feeling and motor function forever
Long property is disabled, and in China, there are about 900,000 new cases every year.Nerve autograft is the common treatment means of neurotrosis, so
And there are many sizes between disadvantage, including defect nerve and Nerve Graft to mismatch for this method;God for extracting donor
Through second operation to be undergone;Donor graft is insufficient;Donor site is also easy to produce neuroma etc..In order to overcome the problems, such as these,
Biodegradable CO2 laser weld socket pipe repairs alternative means as effective, for promoting neurotrosis to regenerate and providing god
Path through growth.
The CO2 laser weld socket pipe having been commercialized at present is usually by the type i collagen of biological source and synthesized degradable biology material
Expect that this two classes material is made, such as polycaprolactone (PCL), poly- (lactide-co-caprolactone) (PCLLA), poly (L-lactic acid)
(PLLA), poly- (D, L- lactic acid-ethanol copolymer) (PLGA) and polyvinyl alcohol (PVA).However, by these biomaterial systems
There are following FAQs for the CO2 laser weld socket pipe made:
1) too fast degradation, this causes early stage to collapse (a few weeks), or too slow degradation (>8 months, even>1 year), it is adjoint
Incomplete or segment degradation;
2) biocompatibility of material is limited, cannot promote the growth of nerve cell;
3) inflammation caused by acid degradation products;
4) flexibility of neural socket pipe is insufficient, and neural residul end during regeneration is caused to be torn from neural socket pipe chamber;
5) cause tube chamber to block and prevent the kink resistance of nerve regneration poor;
6) the extensive inflammation reaction etc. for easily causing fibrosis and nerve regneration being presented;
7) rejection etc. is immunized caused by biogenic material.
Due to the particularity of AltPU material structures and function, manufactured nerve trachea effectively overcomes above shortcoming, makes
It obtains restoration effect and is not only better than nerve autograft, better than nerve socket made of the above degradable polymer
The repairing effect of pipe.
The CO2 laser weld socket pipe that will be prepared in the present embodiment carries out CO2 laser weld experiment in SD rat animal models,
To neural socket pipe and nerve autograft made of Alt-PU and Ran-PU (embodiment 1), PCL, the manufactured set of silicone tube
It takes over the system research for carrying out CO2 laser weld and compares, nerve is evaluated for 80 adult SD rats of 300-350g using weight
Repairing effect.Wherein, Fig. 3 a are CO2 laser weld micrurgy schematic diagram;Fig. 3 b are the CO2 laser weld socket being implanted into rat body
Pipe;Fig. 3 c are that the SEM of the socket pipe prepared by alternating block polyurethane (Alt-PU) schemes.
Animal is divided into 5 groups, every group 15.Dimension scale that neural socket pipe makes is similar to autologous nerve, and (internal diameter is about
1.3mm;Wall thickness about 0.4mm), the sciatic nerve 12mm defects generated by the operation excision of nerve fiber are used as neurotrosis mould
Type, the repairing effect evaluation for neural socket pipe.The yellow Jackets of animal 50mg/kg weight are anaesthetized, the ischium on right side
Nerve exposure, the nerve segment of 12mm is removed from big midleg level.15mm conduits or the nerve of removal are inserted in proximal end in itself
Between distal stump, sutured with No. 8-0 absorbable PLGA suture in each junction.After implantation, stitched using No. 5-0
Zygonema sutures muscle incision, and 2-0 silk suture skins are used in combination.Every rat receives an implantation material, and at identical interval
Time removes.It is postoperative, by every animal feeding in a cage, ad lib and drinking-water.Concentrate to animal carry out autotomy and
The inspection of contracture sign.In each time interval, sciatic nerve function index, electro physiology and histomorphometry are carried out,
To assess the efficiency of CO2 laser weld.All zooperies are according to ISO10993-2:1992 animal welfares require to carry out.
In predetermined time period (postoperative 2,4,8,10 and 14 weeks), nerve regneration is evaluated by walking orbit analysis.In Fig. 4
Middle more different groups of sciatic nerve function index (SFI) value, implantation observe in Alt-PU groups after 14 weeks SFI values be-
24%, restore SFI value -28% higher than autograft group, is much better than -35%SFI the values and PCL groups of Ran-PU groups, silica gel
The SFI values of pipe group.4,8,14 weeks after surgery implantation Alt-PU nerve socket pipes are respectively illustrated in Fig. 5 a, Fig. 5 b and Fig. 5 c
Animal footprint.As can be seen that at 2 and 8 weeks, footprint image is quite narrow and abnormal, and motor function is not completely extensive at this time
It is multiple.It was marked at the 14th week, footprint image restores normal, shows that neuromotor function significantly restores.
Different phase electro physiology injury side peak swing and offside (healthy side) comparative situation are as shown in Figure 6, it can be seen that
AltPU groups just already exceed autotransplantation group on the 4th week.
Implantation 4,8 and 14 weeks after, Alt-PU, Ran-PU, autograft, PCL holders, silicone tube C MAP current potential
Signal compares (the results are shown in Figure 4).Action potential in Alt-PU, Ran-PU, autotransplantation group and PCL holder groups is 4
Zhou Houneng is clearly illustrated, shows that the functional rehabilitation of injured nerve is quick.Current potential becomes stronger after 9 and 14 weeks, shows that nerve is repaiied
Recover lost eyesight aobvious.However surprisingly Alt-PU groups show signal more stronger than autotransplantation group.This shows novel alternating block
The CO2 laser weld socket pipe of polyurethane (Alt-PU) is suitable with the autotransplantation for being considered " goldstandard " in restoration effect,
It is even better.
Embodiment 3
Alternating block polyurethane (Alt-PU) biomaterial prepared in embodiment 1 is applied to the preparation of eyelid holder,
Manufacturing method is liquid-solid phase separation and freeze-drying:
Be put into beaker with a certain amount of Alt-PU materials, be added organic solvent, until Alt-PU be completely dissolved into it is transparent
Solution.Solution is poured into stainless steel mould, liquid level thickness is poured into control, and the mold containing solution is placed in -20-0 DEG C of ice
1-10h in water mixing insulating box, taking-up are placed on 1-24h in -10-4 DEG C, move in freeze drier be lyophilized later, Zhi Houleng
Dry 1-24h is lyophilized, takes out stainless steel mould and is put into ambient temperature vacuum drying machine dry 1-48h, shaped support is taken out in demoulding, then
Holder is cut into 1cm2Holder obtains 0.7mm × 1cm2Eyelid is implanted into holder.It is 10- that this eyelid, which is implanted into holder to have porosity,
99% and aperture be 100nm to 500 μm (micron) porous membrane structure.
The processing method of ADM eyelid holders is commercialized:ADM is put into lyophilized overnight on freeze drier, from freezing
It is taken out on drying machine, holder is then cut into 1cm2。
Important appendicle of the eyelid as eye only has the work(of its protection eyeball of complete form and function competence exertion
Energy.With the continuous improvement of social industrialization degree, the various wounds of eye, especially soda acid chemical injury, thermal burn and machinery
The caused eyelid wound of wound is increased.The defect of eyelid skin, muscle, tarsus, papebral conjunctiva is often resulted in after defect of eyelid, no
Beauty is only influenced, and exposed property ulcer of the cornea is usually caused, and then cause the opacity of the cornea, or even wear due to the exposure of eyeball
It blinds in hole.The damage of eyelid usually requires the part that damage was filled up as tissue substituent or reinforced to different materials.Therefore,
There are many tissues by the reparation, including autologous tissue, allosome tissue and artificial organ etc. of exploitation progress eye wounds.Its
In, the limited sources such as autologous material such as Ear cartilage, hard palate mucous membrane, elasticity and toughness are difficult to meet the requirements, and topography is closed
System is complicated, and operation time-histories is long, needs second of operative incision;The transplanting such as allohisto compatibility such as allogeneic sclera, Homologous dura
Object is different from the antigenicity of body tissue, serious immune rejection can be nearly all faced after implantation, while local inflammation is anti-
Ying Qiang, material are easily degraded and absorbed.So far, it can be very good to be widely used in clinic without a kind of tarsus substitute.
Ideal eyelid substitute should comply with the following conditions:
1) facilitate acquisition and preservation.
2) it operates and is easy in art, only need to simply trim and both can reach operation requirement.
3) price is relatively cheap, and most of patient can afford.
4) there is hardness similar with physiological tissue, thickness and elasticity.
5) host tissue can be facilitated to grow into, and is merged over time with host, it is difficult to differentiated.
6) immunological rejection caused by is slight, inflammatory reaction is small.
7) implantation infectious-related complication is few.
8) said effect can continue for quite a long time, or even lifelong.
Meanwhile being needed in conjunction with the specific function of eye, tarsus substitute should also twinkled with the surface of relative smooth
The cornea under it will not be worn in the process, it is basic after implantation to meet facial symmetrical and protection eyeball effect.
Tarsus is replaced with allogeneic acellular dermal (ADM), all sees that correlative study reports that effect is more both at home and abroad
Ideal is that the relatively broad eyelid of current clinical application substitutes graft.In recent years, with the appearance of organizational project and modern times
The fast development of ophthalmology medicine, the constantly improve of medicine theory, we are with the alternating block polyurethane (AltPU) of the present invention for base
Material prepares the porous support with ultra microstructure by liquid-solid phase partition method and substitutes the dynamic of tarsus progress eyelid reconstruction in situ
Object is tested, and is control with the strong ADM of clinical application dominance, and the foundation of feasibility is obtained from histology and cytology evaluation,
Prove that alternating block polyurethane tarsus timbering material can be used as ideal eyelid substitute to be applied to clinic.
The eyelid prepared in the present embodiment implantation holder is subjected to eyelid repairing test in SD rat animal models.Animal
Operation consent rinses Alt-PU eyelids implantation holder through sterile saline, and ultraviolet ventilation irradiation is sealed afterwards in sterile for 24 hours
It is saved backup in centrifuge tube.
The foundation of animal model:SD rats 30, male, weight 300-350g are randomly divided into 2 groups, every group 15:①
Alt-PU groups;2. ADM groups.Using 1.0% (w/v) yellow Jackets, intraperitoneal injection of anesthesia (40mg/kg), effective rear preserved skin is used
Shaving machine shaves off eye circumference hair, then the entire preserved skin region of routine disinfection, later at the eyebrow of mouse inject 1% lidocaine and
The mixing of 0.75% Bupivacaine (contains 1:100000 adrenaline) subcutaneous infiltration anesthesia.Parallel eyes-affinity is used flat at away from margo palpebrae 2mm
Tweezer rises, and two arc incision lines of skin are drawn with black gel ink pen, is marked at operation opening at the 5mm of canthus both sides, then
Do the skin incision of upper eyelid by mark line, detach two notch subcutaneous tissue and orbicular muscle of eye to tarsus, after finding out tarsus, with aobvious
Micro- clipper for surgical use wipes out 1mm2Size tarsus tissue obtains eyelid tarsal defect model.By ready Alt-PU eyelids holder and
Then the corresponding tarsal defect position of ADM eyelid stenter to implant uses the degradable absorbable suture lines of 8-0 by implantation material and the tarsus broken ends of fractured bone
2 needle of corresponding interrupted suture is interrupted apposition suture skin of upper eyelid and subcutaneous tissue, about 2 needles with 6-0 absorbable sutures, and art finishes, wound
Mouth Pressure bandage.Postoperative SD rats are put into mouse cage, after waiting for its anesthesia to wake up, give sub-cage rearing, it is postoperative
Daily the wound location of observation rat whether there is or not it is red and swollen, infect, fester;Wound pairing situation, whether there is or not split and plant piece to fall off, cruelly
Dew;Whether there is or not damaged and corneal damages for conjunctival surface;Whether there is or not deformations for margo palpebrae;Whether there is or not fornixs to narrow, eyeball adhesion, eyelid movement are abnormal or
Situations such as dysraphism.
The clinical follow result of Alt-PU groups is as shown in Fig. 7 a-7d:A) postoperative one hour, skin incision was degradable with 7-0
Absorb suture suture (shown in Fig. 7 a);B) it is formed there are one small scab within postoperative 24 hours, there is a little slight redness in upper eyelid, does not have
Observe that (shown in Fig. 7 b) occurs for apparent rejection and gangrenous phenomenon;C) hair at postoperative two weeks eyelid surgeries starts to give birth to
It is long, it is observed that (shown in Fig. 7 c) without congested, exudation and inflammatory reaction phenomenon;D) postoperative 4 weeks art branch holes portion be restored to
Preoperative the same, arrow is directed toward operative site (shown in Fig. 7 d).The consciousness of postoperative 1h, rat all restore normal;Postoperative sees mouse for 24 hours
Upper eyelid gently swells, and margo palpebrae suture is in place, and wound pairing is good, and local desiccation is without exudation, a small amount of scab.Eyelid knot is had no after each group implantation
Film is worn out and corneal epithelial wound, and margo palpebrae organizes nothing without exudation and infection without incisura, no hypophasis, notch after implantation
Exposure.It is that 1W, the hair of its art side wound postoperative 2W start to repair completely after surgery that its scab, which is completely fallen off,.Postoperative 2W and
During the art branch hole portion of 8W does not have apparent difference, eyelid to repair, their daily life system is normal, and art branch hole portion also acts normally
Eye opening eye closing activity, with the activity of normal side eye.Occur without significantly rejection, gangrene or inflammatory reaction, it was demonstrated that
Its postoperative eyelid wound restores rapid, it can be seen that, biomaterial of the invention has fine mechanical flexibility, biodegradable
Property and eyelid soft tissue compatibility, can repair very well tarsus damage.
Embodiment 4
Alternating block polyurethane (Alt-PU) biomaterial prepared in embodiment 1 is applied to the system of wound dressing foam
Standby, preparation method is:
It weighs alternating block polyurethane (Alt-PU) biomaterial prepared in 2g embodiments 1 and is dissolved in 40mL water
In, it is made into the solution of a concentration of 50mg/mL, is sufficiently stirred and is poured into the culture dish of 90mm after it is completely dissolved.Again by its turn
Precooling 1-24h in -20 DEG C of refrigerator is moved to, then transfers them to rapidly in -80 DEG C of low temperature refrigerator and freezes 1-24h.It takes
Quickly be transferred in freeze drier, be freeze-dried after go out, taken out afterwards for 24 hours, spongy Alt-PU wound repairs foam
Dressing.This wound repair dressing has the porous foam knot that porosity is 10-99% and aperture is 100nm to 500 μm (micron)
Structure.
Ran-PU wound repairs are prepared using the random block polyurethane (Ran-PU) and the above method prepared in embodiment 1
Foam dressing.
Wound repair is always the hot spot of current medical domain research, currently, the polyurethane material as wound dressing
Rarely found report is studied, since polyurethane high molecule has waterproof and breathable, moisturizing and the function of preventing bacterium from penetrating into, with degradable
PLA and the polyurethane of the good PEG synthesis of biocompatibility have good potentiality as the research of wound dressing.The present invention
PLA, PEG group biodegradable polyurethane material are applied to wound repair for the first time, by the full thickness skin for building SD rats
Model, as a contrast with hospital gauze.Animal test results show:The repairing effect of biomaterial group of the present invention is substantially better than doctor
With gauze, there are application and commercial value well as a kind of novel wound dressing materials.
The Alt-PU wound repairs foam dressing prepared in the present embodiment is carried out wound in SD rat animal models to repair
Retrial is tested.
By building the full thickness skin trauma model of rat, to evaluate the novel degradable polyurethane biomaterial of the present invention
As wound dressing to the curative effect of wound.18 rats (about 300 g) are divided into three groups by random, and every group six is only used as putting down
Row experiment.Intraperitoneal injection of anesthesia agent (10% chloraldurate), dosage 3ml/kg.The hair of area will be tested needed for rat back
It gently strikes off after 70% alcohol disinfecting of number, is cleaned with clear water.Then with disinfection after surgical scissors back cut 10mm ×
The wound size of 10mm, and the surface of a wound is carried out thoroughly to expand wound, the surface of a wound, the surface of a wound are cleaned repeatedly with sterile saline and Iodophor liquid
Thoroughly hemostasis.The area of original wound is recorded with the ruler after sterilizing, and photographs to record data.Experimental group is Alt-PU wounds
Foam dressing group is repaired, as a control group with Ran-PU wound repair foam dressing groups and hospital gauze.It replaces within every two days primary
Dressing records wound size with ruler, and photographs to record wound situation.After ten days, remaining four days no longer more change dressings, record
14 days data for repairing the phase.Contraction of wounds rate is calculated using following formula:Contraction of wounds rate (%)=[(Ao-At)/Ao] ×
100.Wherein Ao is the area of original wound, and At is the wound area in different reparation periods.
After Skin Wounds, wound recovery situation is observed and recorded by way of taking pictures, as a result such as Fig. 8 a-8c
It is shown.It can be found that the skin wound of three groups of rats has a different degrees of contraction, i.e. the skin of edge of wound is to wound center
Mobile, the surface of a wound reduces, this means that wound is constantly healing.The 4th day after wound, the surface of a wound of gauze group and Ran-PU groups all goes out
Show inflammatory exudate and clot, and the wound surface of Alt-PU groups does not have the phenomenon that inflammation, redness and empyema.The 8th after wound
It, the incrustation of gauze group wound, contraction of wounds is slow, and Ran-PU groups still have a small amount of hydrops and blood, but contraction of wounds is better than yarn
Cloth group, the surface of a wound of Alt-PU groups have newborn granulation tissue, the result shows the recovery of the skin of Alt-PU groups is most fast, into
The last repairing phase of skin is entered, thus will be good than preceding two groups of repairing effect.The 14th day after wound, gauze group still has ratio
Obvious scar, shrinking percentage at this time, which is only the contraction of wounds rate of 40%, Ran-PU groups, can reach 80%, and Alt-PU groups
Skin substantially healed completely, and surface is grown with hair, it is difficult to observe the scar of wound.Wherein Fig. 9 is
Wound records wound size, and the contraction of wounds rate as obtained by formula calculating, contraction of wounds rate in repair process, with ruler
It is bigger, illustrate that the surface of a wound is smaller, it is also better to restore.It can be seen that the shrinking percentage of Alt-PU groups is always above other two in Fig. 9
Control group, this result are also consistent with result above.
From gross examination of skeletal muscle it is found that the polyurethane biomaterial of the present invention can provide the effect of protection for wound, and have
Certain acts on every bacterium, can form the surface of a wound of a moistening by absorbing diffusate, be supplied to one good life of cambium
Long environment.Very close, the Ke Yitong additionally, due to the ammonia ester bond in polyurethane macromolecular and the amido bond in human body internal protein
The adherency and growth for promoting the specific effect of cell surface cell are crossed, the healing of wound is accelerated.Along with suitable parent
Hydrophobicity, mechanical property and flexibility etc. all have an impact wound reparation, and alternating block polyurethane of the invention can become
The ideal material of wound repair and skin repair.
The histology pathological analysis of wound repair:The case where in order to further determine skin repair, we took at 14 days
Lower neoplastic skin tissue carries out pathological analysis, as a result as shown in Figure 10 a-10c by HE dyeing to tissue.As front is created
Hinder described in repair mechanisms, is inflammatory reaction first after skin wound is formed, it is the basis of wound healing.This stage master
Have a large amount of inflammatory cell, it removed by phagocytosis, oxidation antimicrobial effect and the effects that activating complement slough and
Foreign matter protects normal structure, prevents infection.Followed by fibroblastic a large amount of proliferation, it is main repair cell,
It is the engineer, builder and administrator of wound repair, it and extracellular matrix, contraction of wounds, the update of collagen and paralysed trace
Formation has close relationship.Finally enter back into the regeneration of the organs such as blood vessel and lymph, i.e. regeneration and revascularization.From
It compares and finds in figure, a large amount of fibroblast (shown in Figure 10 c) occurs in the wound of gauze group, mainly also in the second of reparation
Stage.And the wound of Alt-PU groups can see under the microscope there are many organs such as new vessels, lymph generate (Figure 10 b
It is shown), the institutional framework (Figure 10 a shown in) of closer normal skin obviously smaller than gauze group at fibrosis region, this
Phenomenon also can promote migration of epithelial cells related with PEG in component.From pathological examination, Alt-PU groups are proved again (alternately
Polyurethane material group) repairing effect be significantly better than gauze group.
Embodiment 5
It is porous that alternating block polyurethane (Alt-PU) biomaterial prepared in embodiment 5 is applied to skull complex repairation
The preparation of holder, preparation method are:
The Alt-PU alternating block polyurethane biomaterials prepared in appropriate embodiment 1 are weighed, are put into 20ml vials,
N,N-dimethylformamide to polyurethane is added to be completely dissolved.Weigh sodium chloride particle, the hydroxyapatite (HA) of certain grain size
It is added in polyurethane solutions after shaking mixing in proportion with tricalcium phosphate (TCP), vibrates mixing, mixture is coated on glass slide
On, drying at room temperature 48h is complete to n,N-Dimethylformamide volatilization.Glass slide is placed in ultra-pure water fully dissolving chlorination for 24 hours
Sodium particle is changed the liquid once per 8h, and glass slide is placed in drying at room temperature 48h in vacuum drying chamber to be repaiied to get Alt-PU skulls are compound
Multiple porous support, this holder have the porous foam structure that porosity is 10-99% and aperture is 100nm to 500 μm (micron).
It is compared simultaneously convenient for the reference of holder, we also use polymethyl methacrylate (PMMA) no HA and TCP the case where
Under, porous support is produced as shown in Figure 11 f.
Bone tissue engineer research experienced from no immune function animal to small-sized mammalian, then arrive large mammal,
The stage of most Zhongdao clinic, validity, safety be proved more and more, basic fundamental relative maturity.It is careful planting
In terms of born of the same parents, other than currently used BMSCs, also occur adipose-derived and Cord Blood-Derived stem cell successively, it
Derive from a wealth of sources, osteogenic ability is similar to even better than BMSCs.In terms of timbering material, in addition to previously widely applied different
Other than body bone holder material, occurs timbering material that is a large amount of artificial and naturally extracting at present, it is wide that these materials all have source
General and degradable characteristic, needs of the mechanical strength all close to tissue engineered bone.In terms of constructing technology, weaver is largely organized
The appearance of journey bone bioreactor, the structure for the tissue engineered bone of specific demand provide possibility.Along with bone tissue engineer
The continuous maturation of technology and product, extensive clinical application are possibly realized.
The Tissue Engineering Study of bone is concentrated mainly on two aspects at present:
First, bone tissue induces:Defect is filled using a kind of porosity, biodegradable stent.This holder has self-bone grafting
And osteoconductive potential, the other cells of osteoblast and the region can be caused and grow into and be adsorbed on holder.As matrix is accumulated, bone
Tissue gradually forms, and again moulding.Since it has the potentiality of healing and remodeling, make the poroid substance of non-organic combination with group
It knits and grows into the bone tissue to form organic structure.This substance mainly has bioceramic and poly- fumaryl propylene (PPF).Second is that
Cell delivery:Autologous osteoblasts cell in osteoconductive scaffold or the healing with important work(for bone defect at osteoblast
Can, osteoblast transplanting contributes to bone tissue to grow into be formed with extracellular matrix.Transplanted cells can discharge wide spectrum growth factor rush
Into self-bone grafting and osteanagenesis;Poly α-hydroxylation ester is a kind of up-and-coming cell delivery substance.It is other that there is transfusion cell work(
Can substance have polylactic acid (PLA), polyglycolic acid (PGA) and polylactic acid and polyglycolic acid bifunctional polymerizable object.
Alternating block polyurethane (AltPU) biomaterial using the present invention is the main material of skull regeneration recovery support
Material, is blended with the hydroxyapatite of different content and tricalcium phosphate, and using percolation of saltouing, the three-dimensional for preparing porous structure is multiple
Timbering material is closed, internal stent has high porosity, is mutually communicated between micropore, disclosure satisfy that cell Proliferation migration and tissue fluid
Infiltration exchange, is conducive to the transport of nutriment and metabolite.This holder has good blood compatibility and cytocompatibility
Property.It is fine that holder repairs Rat calvarial damage effect:It shows, props up from morphometric evaluation this holder reparation Rat calvarial damage results
Frame can be cell Proliferation repairing early and middle portion to keep more complete three-dimensional porous rack shape, internal microcellular structure
Space is provided with migration, the holder of later stage higher HA/TCP contents repair skull can damage quickly, and timbering material is also complete
Degradation, is substituted, appearance is no different with normal bone by area of new bone, it was demonstrated that biomaterial of the invention and thus bone made from material is repaiied
Multiple holder can effectively support the effect of skull regeneration reparation.
The foundation of Rat calvarial damage model:10% chloraldurate of adult SD rats (300-350g) presses 0.35ml/100g
Weight intraperitoneal injection of anesthesia, head unhairing, iodine tincture disinfection, calvarium skin 1cm notch, blunt separation periosteum and its surrounding tissue,
Half storey 5x5mm skull defecis are manufactured on the right side of skull with cranial drill, it is compound to be implanted into Alt-PU skulls manufactured in the present embodiment respectively
Repair porous scaffold (experimental group) and HA/TCP compound cranial bones porous support (control group), and fixing bracket, seam concurrent disinfection wound
Mouthful, injection penicillin (400000IU/ml, 0.2ml/kg) continues 7 days, takes skull to carry out in 18 days, 40 days and 80 days after implantation
Morphological observation and pathological staining observation, the Alt-PU skulls of the different HA contents of scanning electron microscope (SEM) the observation display present invention
Complex repairation porous support internal structure is as shown in Figure 11 a-11e.
Pathological observation and coloration result show:Postoperative 18 days, the skull defeci region of control group was without significant change;In holder
In the experimental group of implantation, cell has dissociated into inside skull porous support and starting to be proliferated, cell it is loose be distributed in holder
Inside, osteocyte and osteoclast obviously show, and have more New born formation.Postoperative 40 days, control group skull defeci region
Without significant change;Experimental group internal stent cell showed increased, new bone largely generate, and skull defeci region is in closure trend;Portion
Point experimental group skull defeci region has almost been closed completely.Postoperative 80 days, it is new that the defect area of control group grows a thin layer
Bone, in skull porous support group, defect heals completely, and holder is all degraded.Skull porous support (the experiment of the present invention
Group) repair Rat calvarial damage effect it is fine.Rat calvarial damage results are repaired from morphometric evaluation experiment pack support to show:Branch
Frame can be cell Proliferation repairing early and middle portion to keep more complete three-dimensional porous rack shape, internal microcellular structure
Space is provided with migration, skull porous support repair skull can damage quickly, and the timbering material later stage is also completely degraded quickly,
It is substituted by area of new bone, appearance is no different with normal bone, it was demonstrated that this timbering material can effectively support the effect of skull regeneration reparation.
Rat calvarial injury repair:The half storey skull defeci region of mouse is obviously observed from Figure 12 a.Alt-PU holders are planted
After entering defect 18 days, it can obviously observe holder form, be attached at defect, be surrounded by one layer of fibr tissue
(shown in Figure 12 b).40 days after surgery, the skull defeci region of control group was without apparent healing phenomenon (shown in Figure 12 c).Implantation
After Alt-PU holders 80 days, Alt-PU holders have been completely degraded, and (Figure 12 d institutes are repaired in skull defeci region completely
Show).
It is other exemplary embodiments below, any type of limitation is not done to the present invention.
Embodiment 6:A kind of alternating block polyurethane (AltPU) is provided, is a kind of copolymer, including one or two kinds of fat
Fat race polyester segment, such as PLA, PHA, PHB, PCL, PCLLA, PLGA;Can include a hydrophilic segment, such as poly- second simultaneously
Glycol (PEG), polypropylene glycol (PPG), polytetramethylene glycol (PBG), PolyTHF (PTHF) or ethylene glycol, propylene glycol, butanediol
Small molecule dihydric alcohol, trimethylolpropane (TMP) polyalcohol, it is amphipathic to obtain, that is, it is provided simultaneously with hydrophily and hydrophobicity
Copolymer.
Embodiment 7:A kind of alternating block polyurethane (AltPU) is provided, aliphatic polyester binary alcohol and two isocyanides are passed through
Hydrophilicrto polyether the segment such as PEG, PPG, PBG or aliphatic polyether glycol of acid esters sealing end and diisocyanate terminated fat
It is prepared by the selective coupling reaction between fat race polyester diol segment.Aliphatic polyester binary alcohol segment can be PLA, PHA,
PHB, PCL, PGA, PCLLA, PLGA.Aliphatic diisocyanate used is hexamethylene diisocyanate, two isocyanide of lysine
Acid esters, fourth diisocyanate, isophorone diisocyanate, 4,4'- di-2-ethylhexylphosphine oxides (cyclohexyl) diisocyanate etc., for closing
At the diisocyanate terminated segment in selective coupling reaction;Selective coupling reaction is by tin catalyst such as 2- ethyl hexyls
Sour tin (II), butyl is dibutyltindilaurate catalyzed or does not use catalyst;Under an inert atmosphere in ontology or organic molten
Selective coupling reaction is carried out in agent.
Embodiment 8:A kind of alternating block polyurethane is provided, is the poly- ammonia of alternating block based on aliphatic polyester and polyethers
Ester (Alt-PU).
Embodiment 9:The alternating block polyurethane material is in the application of other biomedical sectors, including Bone Defect Repari branch
The applications such as frame, skin reconstruction and reparation, Antiadhesive film, vascular repair film, meninx, ligament and tendon reparation.
With the polymer phase ratio of random block polyurethane design, the design of alternating block polyurethane can generate more regular table
Face structure;With the polymer phase ratio of random block polyurethane design, alternating block polyurethane designs the polymerization that can generate enhancing
Object is separated.
The alternating block polyurethane (AltPU) has improved medicine, machinery and processing performance, while having minimum
The degradation property that degradation pH changes and can well control.
Alternating block polyurethane material described in embodiment 7 is applied to CO2 laser weld socket pipe and other soft tissues and firmly
Regeneration, implantable medical device and non-implanted medical device.
The medical treatment of this project degradable biomaterial possible application and beauty product (including but is not limited to):
1. soft tissue regeneration reparation is used for, such as Peripheral nerve repair socket pipe, Peripheral nerve repair coating film, peripheral nerve
Restoration and protection piece;Artificial skin regenerates;
2. biodegradable coating, such as the degradable drug-carried coat of intravascular stent, foot fungus infection treats drug-carried coat;
3. adherence preventing material, such as operation antiblocking film, cranium brain film;
4. repair of cartilage holder, such as meniscal repairs porous plate, eyelid reconstruction holder;
5. wound repair film and dressing, such as liquid adhesive bandage, negative pressure drainage dressing, hemostatic yarn, ear nose hemostasis cotton;
6. bone complex repairation holder, such as skull complex repairation holder;
7. special medical absorbable suture, such as elastic force medical absorbable suture;
8. it is other can et al. Ke medical instrument and medical and beauty treatment product, as hernia repair sticking patch, soft tissue lift belt
The preparation of (line).
It is above-described to be merely a preferred embodiment of the present invention, it should be understood that the explanation of above example is only used
In facilitating the understanding of the method and its core concept of the invention, it is not intended to limit the scope of protection of the present invention, it is all the present invention's
Any modification for being made within thought and principle, equivalent replacement etc., should all be included in the protection scope of the present invention.
Claims (10)
1. a kind of novel degradable polyurethane biomaterial, it is characterised in that:Including several first formed by first polymer
Block, several the second blocks formed by second polymer, the first block and the second block are alternately arranged, the first adjacent block
And second be keyed to form alternating block polyurethane (AltPU) by carbamate between block, the as described novel degradable
Polyurethane biomaterial.
2. a kind of novel degradable polyurethane biomaterial according to claim 1, it is characterised in that:First block
With the second block random alignment, it is keyed to be formed without returning block by carbamate between adjacent the first block and the second block
Polyurethane (RanPU) degradable polyurethane biomaterial.
3. a kind of novel degradable polyurethane biomaterial according to claim 1 or 2, it is characterised in that:Described first
Polymer is the polyester of dihydric alcohol sealing end, and the second polymer is diisocyanate terminated aliphatic polyether or aliphatic poly
Ester polymer, the second polymer can also be substituted by aliphatic dihydroxy alcohol.
4. a kind of novel degradable polyurethane biomaterial according to claim 3, it is characterised in that:Second polymerization
Object aliphatic dihydroxy alcohol is ethylene glycol or 1,4- butanediols.
5. a kind of novel degradable polyurethane biomaterial according to claim 3, it is characterised in that:The dihydric alcohol envelope
The polyester at end is that aliphatic polyester or different aliphatic polyesters combine the copolymer to be formed;The diisocyanate is aliphatic two
Isocyanates, specially hexamethylene diisocyanate, fourth diisocyanate, lysine diisocyanate, lysine ester two are different
One kind in cyanate, isophorone diisocyanate, 4,4' methylene bis (cyclohexyl) diisocyanate.
6. the preparation method of novel degradable polyurethane biomaterial described in a kind of claim 1, with the first polymer and
Second polymer is reaction raw materials, is reacted 8~72 hours at 30~100 DEG C, obtains the alternating block polyurethane.
7. a kind of preparation method of novel degradable polyurethane biomaterial according to claim 6, it is characterised in that:Institute
It states reaction to carry out in reaction raw materials ontology or organic solvent, organotin catalysts can also be added in reaction system.
8. a kind of preparation method of novel degradable polyurethane biomaterial according to claim 6, it is characterised in that:Institute
It is identical with the molar ratio of isocyanate groups to state hydroxyl in reaction raw materials.
9. novel degradable polyurethane biomaterial described in claim 1 is preparing degradable implantation and non-implantable medical device
Using.
10. according to claims require the 9 novel degradable polyurethane biomaterials prepares it is degradable implantation with it is non-
The application of the application of implantable medical device, it is characterised in that:The degradable implantation and non-implantable medical device are included in nerve
Reparation socket pipe, meniscal repairs, resist blocking and that film, meninx, eyelid reconstruction holder, wound repair film or/dressing,
Or cartilage and bone complex repairation holder, artificial skin, biodegradable coating, adherence preventing material, special absorbable operation stitching
Line or it is other can et al. Ke medical instrument and medical and beauty treatment product preparation;
The medical treatment of this project degradable biomaterial possible application and beauty product (including but is not limited to):
1. soft tissue regeneration reparation is used for, such as Peripheral nerve repair socket pipe, Peripheral nerve repair coating film, Peripheral nerve repair
Screening glass;Artificial skin regenerates;
2. biodegradable coating, such as the degradable drug-carried coat of intravascular stent, foot fungus infection treats drug-carried coat;
3. adherence preventing material, such as operation antiblocking film, cranium brain film;
4. repair of cartilage holder, such as meniscal repairs porous plate, eyelid reconstruction holder;
5. wound repair film and dressing, such as liquid adhesive bandage, negative pressure drainage dressing, hemostatic yarn, ear nose hemostasis cotton;
6. bone complex repairation holder, such as skull complex repairation holder;
7. special medical absorbable suture, such as elastic force medical absorbable suture;
8. it is other can et al. Ke medical instrument and medical and beauty treatment product, if hernia repair sticking patch, soft tissue lift belt (line)
It prepares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017104624953 | 2017-06-19 | ||
| CN201710462495.3A CN107686546A (en) | 2017-06-19 | 2017-06-19 | A kind of novel degradable polyurethane biomaterial and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108409938A true CN108409938A (en) | 2018-08-17 |
Family
ID=61152683
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710462495.3A Pending CN107686546A (en) | 2017-06-19 | 2017-06-19 | A kind of novel degradable polyurethane biomaterial and its preparation method and application |
| CN201810111018.7A Pending CN108409938A (en) | 2017-06-19 | 2018-02-07 | A kind of novel degradable polyurethane biomaterial and its preparation method and application |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710462495.3A Pending CN107686546A (en) | 2017-06-19 | 2017-06-19 | A kind of novel degradable polyurethane biomaterial and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN107686546A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111072911A (en) * | 2019-11-29 | 2020-04-28 | 苏州林华医疗器械股份有限公司 | Super-lubricating catheter material |
| CN114634641A (en) * | 2022-03-31 | 2022-06-17 | 重庆大学 | Use of porous polymer films with regular porosity for producing anti-adhesive films |
| CN117462769A (en) * | 2023-11-08 | 2024-01-30 | 广州昊毅新材料科技股份有限公司 | Intervention medical degradable adhesive film material and preparation method thereof |
| CN118436859A (en) * | 2023-07-27 | 2024-08-06 | 四川大学 | Application of porous scaffold in preparation of medicine for treating wound |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108503768A (en) * | 2018-04-26 | 2018-09-07 | 代清燕 | A kind of degradable polyester biomaterial and its application in CO2 laser weld socket pipe |
| US20210228770A1 (en) * | 2018-06-05 | 2021-07-29 | Corneat Vision Ltd. | A synthetic ophthalmic graft patch |
| CN108721771B (en) * | 2018-06-29 | 2021-12-28 | 四川大学 | Subcutaneous silicone tube device for regeneration of soft tissues of small animals and application |
| CN109851744B (en) * | 2018-12-21 | 2021-02-05 | 苏州为尔康生物科技有限公司 | Degradable polyurethane biomaterial and preparation method and application thereof |
| CN115521430B (en) * | 2021-09-24 | 2023-10-13 | 苏州瑞济诺医疗科技有限责任公司 | Preparation method and application of organometallic catalyst and degradable biological material |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101397361A (en) * | 2008-11-03 | 2009-04-01 | 重庆大学 | Multi-block polyurethane shape memory high molecule material and preparation method thereof |
| CN101460203A (en) * | 2006-06-02 | 2009-06-17 | 瑞士联邦苏黎世技术大学 | Porous membrane comprising a biocompatible block-copolymer |
| CN101885826A (en) * | 2010-07-28 | 2010-11-17 | 重庆大学 | Biodegradable polyurethane material and preparation method based on piperazine block D, L-polylactic acid |
| CN102516555A (en) * | 2011-11-24 | 2012-06-27 | 北京旭阳化工技术研究院有限公司 | Biodegradable branched aliphatic polyester multi-block copolymer and preparation method thereof |
| CN104356345A (en) * | 2014-12-01 | 2015-02-18 | 四川大学 | Fluorescent graft degradable block polyurethane, bone repair material and preparation method thereof |
| CN104387553A (en) * | 2014-11-20 | 2015-03-04 | 浙江大学 | Biodegradable unsaturated polyurethane material and preparation method thereof |
| CN104744661A (en) * | 2015-03-03 | 2015-07-01 | 宁波市医疗中心李惠利医院 | Hydrophilic degradable segmented polyurethane as well as preparation method and application thereof |
| CN104788695A (en) * | 2015-05-15 | 2015-07-22 | 山东师范大学 | Preparation method of biodegradable polyurethane film material |
-
2017
- 2017-06-19 CN CN201710462495.3A patent/CN107686546A/en active Pending
-
2018
- 2018-02-07 CN CN201810111018.7A patent/CN108409938A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101460203A (en) * | 2006-06-02 | 2009-06-17 | 瑞士联邦苏黎世技术大学 | Porous membrane comprising a biocompatible block-copolymer |
| CN101397361A (en) * | 2008-11-03 | 2009-04-01 | 重庆大学 | Multi-block polyurethane shape memory high molecule material and preparation method thereof |
| CN101885826A (en) * | 2010-07-28 | 2010-11-17 | 重庆大学 | Biodegradable polyurethane material and preparation method based on piperazine block D, L-polylactic acid |
| CN102516555A (en) * | 2011-11-24 | 2012-06-27 | 北京旭阳化工技术研究院有限公司 | Biodegradable branched aliphatic polyester multi-block copolymer and preparation method thereof |
| CN104387553A (en) * | 2014-11-20 | 2015-03-04 | 浙江大学 | Biodegradable unsaturated polyurethane material and preparation method thereof |
| CN104356345A (en) * | 2014-12-01 | 2015-02-18 | 四川大学 | Fluorescent graft degradable block polyurethane, bone repair material and preparation method thereof |
| CN104744661A (en) * | 2015-03-03 | 2015-07-01 | 宁波市医疗中心李惠利医院 | Hydrophilic degradable segmented polyurethane as well as preparation method and application thereof |
| CN104788695A (en) * | 2015-05-15 | 2015-07-22 | 山东师范大学 | Preparation method of biodegradable polyurethane film material |
Non-Patent Citations (3)
| Title |
|---|
| GUANGYAO LI等: "Alternating block polyurethanes based on PCL and PEG as potential nerve regeneration materials", 《JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A》 * |
| JUEYU PAN等: "Alternative block polyurethanes based on poly(3-hydroxybutyrate-co-4-hydroxybutyrate) and poly(ethylene glycol)", 《BIOMATERIALS》 * |
| YUQING NIU等: "Synthesis, Characterizations and Biocompatibility of Novel Block Polyurethanes Based on Poly(lactic acid) (PLA) and Poly(3-hydroxybutyrate-co-4-hydroxybutyrate) (P3/4HB)", 《JOURNAL OF INORGANIC AND ORGANOMETALLIC POLYMERS AND MATERIALS》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111072911A (en) * | 2019-11-29 | 2020-04-28 | 苏州林华医疗器械股份有限公司 | Super-lubricating catheter material |
| CN111072911B (en) * | 2019-11-29 | 2022-02-11 | 苏州林华医疗器械股份有限公司 | Super-lubricating catheter material |
| CN114634641A (en) * | 2022-03-31 | 2022-06-17 | 重庆大学 | Use of porous polymer films with regular porosity for producing anti-adhesive films |
| CN118436859A (en) * | 2023-07-27 | 2024-08-06 | 四川大学 | Application of porous scaffold in preparation of medicine for treating wound |
| CN118436859B (en) * | 2023-07-27 | 2024-12-13 | 成都越见口腔技术有限公司 | Use of a porous stent in preparing a medicine for treating wounds |
| CN117462769A (en) * | 2023-11-08 | 2024-01-30 | 广州昊毅新材料科技股份有限公司 | Intervention medical degradable adhesive film material and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107686546A (en) | 2018-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108409938A (en) | A kind of novel degradable polyurethane biomaterial and its preparation method and application | |
| Bhardwaj et al. | 3D functional scaffolds for skin tissue engineering | |
| Zhong et al. | Tissue scaffolds for skin wound healing and dermal reconstruction | |
| Mohamed et al. | Nanomaterials and nanotechnology for skin tissue engineering | |
| Fujimoto et al. | In vivo evaluation of a porous, elastic, biodegradable patch for reconstructive cardiac procedures | |
| US7919112B2 (en) | Implantable tissue compositions and method | |
| Ludwicka et al. | Medical and cosmetic applications of bacterial nanocellulose | |
| TW200403268A (en) | Biodegradable polyurethane/urea compositions | |
| SK79698A3 (en) | Implantable acrylamide copolymer hydrogel for therapeutic uses | |
| Ågren | Wound healing biomaterials-volume 2: functional biomaterials | |
| JPWO2011021712A1 (en) | Cell / tissue supply support, cell / tissue supply body and production method thereof, tissue regeneration method, and porous body production method | |
| US20100158982A1 (en) | Sheet for guiding regeneration of mesenchymal tissue and production method thereof | |
| CN100368534C (en) | Biologically derived amniotic membrane, composite biologically derived amniotic membrane and preparation method thereof | |
| Jagga et al. | Chitosan-based scaffolds in tissue engineering and regenerative medicine | |
| Khosrowpour et al. | Translation Prospects of a Novel ECM‐Silk Fibroin/Alginate 3D‐Printed Scaffold for Treatment of Full‐Thickness Skin Wounds: An in Vitro and in Vivo Study | |
| JP5886048B2 (en) | Minimal tissue adherent implantable material | |
| Mathews | Polydioxanone: applications in surgery and tissue engineering | |
| KR100644078B1 (en) | Dermal substitute consisting of amnion and biodegradable polymer, the preparation method and the use thereof | |
| Kailani et al. | Synthetic biomaterials for skin tissue engineering | |
| Lo Monte et al. | Biocompatibility and biodegradability of electrospun PHEA-PLA scaffolds: Our preliminary experience in a murine animal model | |
| RU2316290C2 (en) | Gauze endoprosthesis usable in plastic surgery | |
| JP2009513290A (en) | Scleral buckling band and manufacturing method thereof | |
| JP2002065247A (en) | Cell culture substrate | |
| US20190374676A1 (en) | A cross-linked structure for tissue regeneration and engineering and the method for synthesising same | |
| US20240245828A1 (en) | 3D Printed Scaffold Structures and Methods of Fabrication |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180817 |